Genesis Therapeutics, a London-based biotech company specializing in AI, receives funding from NVentures, NVIDIA's corporate venture capital arm, to develop its GEMS platform for drug discovery.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing